Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

April 30, 2002

Study Completion Date

April 30, 2002

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

AVP-923

Trial Locations (17)

10032

Columbia-Presbyterian Center Neurological Institute, New York

13210

State University of New York, Syracuse

19107

MCP-Hahnemann University Dept. of Neurology, Philadelphia

Penn Neurological Institute, Philadelphia

21287

Johns Hopkins University, Baltimore

27157

Wake Forest University, Winston-Salem

28203

Carolinas Medical Center Carolinas Neuromuscular/ALS-MDA Center, Charlotte

33136

University of Miami Dept. of Neurology, Miami

44195

Cleveland Clinic Foundation, Cleveland

53792

University of Wisconsin ALS Clinical Research Center, Madison

60611

Northwestern Medical School, Chicago

78229

University of Texas Health Science Center @ San Antonio, San Antonio

80262

University of Colorado Health Sciences, Denver

90095

UCLA School of Medicine Dept. of Neurology, Los Angeles

92354

Loma Linda University Dept. of Neurology, Loma Linda

94143

University of California, San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY

NCT00021697 - Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS | Biotech Hunter | Biotech Hunter